

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 30, 2021

Heat Biologics, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35994

(Commission File Number)

26-2844103

(IRS Employer Identification No.)

627 Davis Drive,

Suite 400

Morrisville, North Carolina 27560

(Address of principal executive offices and zip code)

(919) 240-7133

(Registrant's telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0002 par value per share	HTBX	The Nasdaq Stock Market (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

Heat Biologics, Inc. (the "Company") unveiled its new RapidVax® cellular vaccine platform at the 2021 World Vaccine & Immunotherapy Antiviral Congress. RapidVax is designed as a rapid programmable vaccine affording the Company the ability to target a comprehensive range of emerging biological threats. The Company is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021, titled 'RapidVax®'- A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats.

The information in this Item 7.01 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 8.01. Other Events

The Company unveiled its new RapidVax® cellular vaccine platform at the 2021 World Vaccine & Immunotherapy Antiviral Congress. RapidVax is designed as a rapid programmable vaccine to target a comprehensive range of emerging biological threats. The Company is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021, titled 'RapidVax®'- A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats. RapidVax leverages the immune-activating properties of heat shock protein gp96, a danger-signal associated protein. A copy

of the poster presentation is attached as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1 104	Presentation titled 'RapidVax®' - A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 30, 2021

HEAT BIOLOGICS, INC.



By: /s/ Jeffrey Wolf
Name: Jeffrey Wolf
Title: Chairman, President and
Chief Executive Officer

'RapidVax'® – A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats

David Lippsetz¹, Padmini Jayaraman², Eric Dixon³, Ryan Kane¹, Anissa Strub¹, Jeff Wolf¹, Matthew Seavey²

¹ Anissa Strub, LLC, 8 Green Drive, Rockville, Maryland 20850
² Biotechnology Resource Center, National Institute of Health, Bethesda, MD 20892
³ Applied Proteins, University of Illinois, Urbana, Illinois 61801

The current COVID-19 pandemic underscores the need for a proven, safe, cost-effective strategy that can be engineered and modified in real time to address emerging biological threats, whether by an intentional attack, an accidental release, or naturally occurring SPT in an infectious disease pathogen. The current pandemic highlights the need for a proven, safe, cost-effective strategy that can be engineered and modified in real time to address emerging biological threats, whether by an intentional attack, an accidental release, or naturally occurring SPT in an infectious disease pathogen. The current pandemic highlights the need for a proven, safe, cost-effective strategy that can be engineered and modified in real time to address emerging biological threats, whether by an intentional attack, an accidental release, or naturally occurring SPT in an infectious disease pathogen.



RapidVax is built on 20 years of research using g90 as a potent antigen-delivery & adjuvant platform. It incorporates g90 and various T cell adjuvants to generate a highly potent and long-lasting T cell response.

INTRODUCING RAPIDVAX "PLUS-AND-PLAY" VACCINE PLATFORM




Designed to Enable Manufacturing and Packaging of Unopposed g90-based Vaccine

RapidVax is a cell-free system. RapidVax is designed to be manufactured and packaged as a single, stable, and easy-to-handle product.

RapidVax is available to manufacturing to rapidly respond to any biological threat. It is a proven, safe, and cost-effective platform for the development and manufacturing of cellular, adjuvanted, vaccine.

RAPIDVAX PROTOTYPE VACCINES



Demonstrated Efficacy in H5N1 Avian Model of Disease

RapidVax is a cell-free system. RapidVax is designed to be manufactured and packaged as a single, stable, and easy-to-handle product.

RapidVax® – A Novel Cellular Vaccine Platform Against Rapidly Emerging Biological Threats

For inquiries or questions please send a request to: info@biotech.bio